Clinical
For Advanced Oesophageal Squamous Cell Carcinoma, PD-1 Antibody Combined with Chemotherapy Improves Progression-Free Survival Compared with Monotherapy or Chemotherapy Alone as First-Line Treatment: A Retrospective Study with Prognostic Biomarker Analysis
A retrospective study evaluated the efficacy and safety of first-line camrelizumab combined with chemotherapy (nab-paclitaxel and cisplatin) for advanced oesophageal squamous cell carcinoma (OSCC), compared to PD-1 monotherapy or chemotherapy alone. The study, involving 253 patients, demonstrated that the combination significantly improved progression-free survival (PFS) compared to the other arms. Although objective response and disease control rates did not differ, median overall survival was longest in the combination group (12.0 months). Adverse events were manageable, with higher rates of anemia and neutropenia in the combination group. An elevated neutrophil-to-lymphocyte ratio (NLR) was identified as an independent prognostic biomarker.